RPS15B Antibody

What is RPS15 and why is it significant in research?

RPS15 (ribosomal protein S15), also known as RIG protein or Small ribosomal subunit protein uS19, is a 145 amino acid protein belonging to the universal ribosomal protein uS19 family. It functions as a ribosomal small subunit protein with a molecular weight of 17 kDa . Recent research has highlighted its significance in cancer biology, particularly its role in promoting esophageal squamous cell carcinoma (ESCC) progression via the p38 MAPK signaling pathway . Its clinical significance is underscored by the correlation between high RPS15 expression and poor prognosis in ESCC patients .

What are the key specifications researchers should know about RPS15 antibodies?

RPS15 antibodies are typically rabbit polyclonal antibodies that detect endogenous levels of total RPS15 protein . Most commercially available antibodies are unconjugated and purified through antigen affinity purification . They demonstrate reactivity with human, mouse, and rat samples, with predicted reactivity in several other species including bovine (99%), chicken (100%), porcine (100%), and Xenopus (95%) . The typical storage recommendation is -20°C, with stability for one year after shipment .

What applications are RPS15 antibodies validated for?

RPS15 antibodies have been validated for multiple experimental applications:

It's critical to note that optimal dilutions are often sample-dependent and may require titration in each specific testing system .

How should researchers design validation experiments for RPS15 antibody specificity?

When validating RPS15 antibody specificity, researchers should employ multiple complementary approaches. Start with Western blotting using positive controls such as human liver tissue, HeLa cells, or mouse brain tissue where RPS15 expression has been confirmed . The expected molecular weight of 17 kDa should be observed. For knockout validation, implement CRISPR-Cas9 RPS15 knockout cells (as demonstrated in KYSE150 and KYSE510 cell lines) alongside wild-type controls.

Additionally, peptide competition assays can confirm specificity, where pre-incubation of the antibody with excess immunogenic peptide should abolish signal. For cross-validation, compare results with at least one alternative RPS15 antibody from a different vendor or clone. Finally, orthogonal validation using mRNA detection methods like RT-qPCR can confirm that protein expression patterns correlate with transcript levels .

What are the optimal antigen retrieval methods for IHC applications with RPS15 antibodies?

For immunohistochemistry applications, optimal antigen retrieval methods have been empirically determined. The primary recommended approach is heat-induced epitope retrieval (HIER) using TE buffer at pH 9.0 . Alternatively, citrate buffer at pH 6.0 can also be used for antigen retrieval, though this may result in slightly different staining intensities and should be validated for specific tissue types . The antigen retrieval step is particularly critical when working with formalin-fixed paraffin-embedded (FFPE) tissues, where protein cross-linking can mask epitopes. For tissues with high endogenous peroxidase activity, researchers should include appropriate blocking steps to minimize background staining.

What controls are essential when using RPS15 antibodies in cancer research?

When conducting cancer research with RPS15 antibodies, several controls are essential:

• Positive tissue controls: Include known positive samples such as human liver tissue, lymphoma tissue, or cancer tissues where RPS15 expression has been confirmed .

• Negative controls: Include primary antibody omission controls and ideally RPS15 knockout or knockdown samples, as demonstrated in studies utilizing sgRPS15 in KYSE150 and KYSE510 cell lines .

• Normal adjacent tissue: When analyzing cancer specimens, include normal adjacent tissue for comparative analysis, as IHC analysis has revealed higher expression of RPS15 in tumors compared to normal tissue (t-test, P = 6.00E−45) .

• Isotype controls: Include matched isotype controls (rabbit IgG) to assess non-specific binding.

• Gradient expression samples: When available, include samples with known differential expression of RPS15, such as the cell line panel described in supplementary data showing varying RPS15 expression levels across KYSE30, KYSE150, KYSE450, and KYSE510 cells .

How can RPS15 antibodies be utilized in studying cancer metastasis mechanisms?

RPS15 antibodies are powerful tools for investigating cancer metastasis mechanisms, particularly in esophageal squamous cell carcinoma (ESCC). Research has shown that RPS15 significantly promotes metastatic potential through multiple mechanisms. Researchers can employ RPS15 antibodies in immunoblotting and immunohistochemistry to correlate RPS15 expression levels with metastatic behavior .

For mechanistic studies, combine RPS15 expression analysis with pathway activation assessment, particularly focusing on the p38 MAPK signaling pathway components that RPS15 has been shown to regulate . Co-immunoprecipitation experiments using RPS15 antibodies can identify interaction partners such as IGF2BP1, revealing how RPS15 regulates mRNA stability and translation of metastasis-promoting factors .

Tissue microarray analysis with RPS15 antibodies has successfully demonstrated correlation between increased RPS15 expression and lymph node metastasis (Fisher exact test, P = 0.018) . Researchers can also use RPS15 antibodies in combination with ptychographic QPI label-free imaging techniques to assess how RPS15 modulation affects cell movement, track speed, and invasion capabilities in real-time experiments .

What is the role of RPS15 in translational regulation and how can it be studied?

RPS15, as a ribosomal protein, plays critical roles in translational regulation that extend beyond its structural role in the ribosome. To study these functions, researchers can employ multiple complementary approaches. RPS15 antibodies are essential for ribosome profiling experiments, where immunoprecipitation of RPS15 can help isolate specific ribosome populations to analyze associated mRNAs.

Research has revealed that RPS15 interacts with IGF2BP1 to promote stabilization of MKK6 and MAPK14 mRNA in an m6A-dependent manner, and promotes translation of core p38 MAPK pathway proteins . To investigate such mechanisms, researchers should combine RPS15 antibodies with RNA immunoprecipitation (RIP) assays to identify mRNAs directly regulated by RPS15. Additionally, polysome profiling with subsequent RPS15 immunoblotting across fractions can reveal the association of RPS15 with actively translating ribosomes.

For functional validation, researchers can employ RPS15 knockdown or knockout approaches as demonstrated in ESCC cell lines, followed by quantification of target protein synthesis using methods such as puromycin incorporation assays or targeted proteomics .

How can researchers use RPS15 antibodies to explore its potential as a therapeutic target?

Recent research has identified RPS15 as a promising therapeutic target, particularly in ESCC. Researchers can use RPS15 antibodies to screen potential inhibitors and evaluate target engagement . A methodological approach would include:

• High-throughput screening: Use RPS15 antibodies in immunofluorescence or ELISA-based assays to screen compound libraries for molecules that modulate RPS15 expression or localization.

• Target validation: Employ immunoblotting and IHC with RPS15 antibodies to validate target engagement in cell lines, patient-derived xenografts, and clinical samples.

• Combination therapy assessment: As demonstrated with folic acid and cisplatin combinations, RPS15 antibodies can quantify changes in RPS15 expression or activity following treatment with various therapeutic combinations .

• Pathway analysis: Use RPS15 antibodies alongside antibodies targeting the p38 MAPK pathway components to determine how potential therapeutics affect downstream signaling.

• Clinical correlation: Perform IHC on patient samples with RPS15 antibodies before and after treatment to correlate changes in RPS15 expression with treatment response, as high RPS15 expression has been linked to poor prognosis in ESCC patients .

What are common pitfalls in RPS15 antibody-based experiments and how can they be avoided?

Several technical challenges can arise when working with RPS15 antibodies:

• Non-specific binding: This commonly occurs in Western blotting and IHC applications. To minimize this issue, optimize blocking conditions (use 5% BSA or milk), ensure proper antibody dilutions (starting with manufacturer recommendations of 1:500-1:2400 for WB and 1:400-1:1600 for IHC) , and include appropriate controls including isotype controls.

• Variable signal strength across tissues: RPS15 expression varies naturally across different tissues and cell types. Researchers should standardize protein loading for Western blots and optimize exposure times. For IHC, tissue-specific optimization of antigen retrieval methods is crucial, with both TE buffer (pH 9.0) and citrate buffer (pH 6.0) being viable options depending on the tissue type .

• Epitope masking: Post-translational modifications or protein interactions may mask antibody epitopes. If signal is unexpectedly weak, try alternate antibody clones recognizing different epitopes or modify lysis conditions to better preserve epitope accessibility.

• Fixation artifacts in IHC/ICC: Overfixation can reduce epitope availability. Standardize fixation protocols (typically 10% neutral buffered formalin for 24-48 hours) and optimize antigen retrieval methods for each specific tissue type being analyzed .

• Batch-to-batch variability: When possible, use the same antibody lot for comparative experiments or include standard samples across blots/staining runs to normalize for lot variations.

How should researchers interpret discrepancies between RPS15 protein and mRNA expression data?

Discrepancies between protein levels (detected by RPS15 antibodies) and mRNA expression are common in biological systems and can provide important insights into post-transcriptional regulation. When faced with such discrepancies, researchers should consider several interpretations and follow-up experiments:

• Post-transcriptional regulation: RPS15, as a ribosomal protein, is subject to complex regulation. Discrepancies may indicate active regulation at the level of translation or protein stability. Quantify protein half-life using cycloheximide chase experiments with RPS15 antibodies.

• Technical considerations: Verify the specificity of both protein and mRNA detection methods. For protein detection, confirm antibody specificity using knockout controls; for mRNA, ensure primer specificity and efficient amplification across all samples.

• Feedback mechanisms: RPS15 may participate in autoregulatory feedback loops. Investigate this possibility by modulating RPS15 expression and measuring effects on both its mRNA and protein levels.

• Spatial regulation: Consider that whole-tissue measurements may mask cell-type specific regulation. Use RPS15 antibodies for single-cell analyses or spatial transcriptomics approaches to resolve cell-type specific discrepancies.

• Temporal delays: Protein production lags behind transcription. Time-course experiments with both RPS15 antibodies and mRNA quantification can resolve temporal discrepancies that might be missed in single time-point analyses.

What methodological approaches should be used when analyzing RPS15 expression in heterogeneous tissue samples?

Analyzing RPS15 expression in heterogeneous tissues presents unique challenges that require specialized methodological approaches:

• Tissue microdissection: Prior to Western blotting with RPS15 antibodies, employ laser capture microdissection to isolate specific cell populations, ensuring the signal represents the cells of interest rather than the bulk tissue.

• Multiplex immunofluorescence: Combine RPS15 antibodies with cell-type specific markers (e.g., epithelial, stromal, immune cell markers) to quantify expression in distinct cell populations within the same tissue section.

• Digital pathology approaches: Implement whole-slide imaging with RPS15 IHC followed by computational image analysis to quantify expression patterns across different regions and cell types within heterogeneous tissues.

• Single-cell analysis: When possible, dissociate tissues and perform single-cell Western blotting or flow cytometry with RPS15 antibodies to obtain cell-specific expression profiles.

• Spatial normalization: For tissue microarray analysis, normalize RPS15 expression to cell-type specific markers, as demonstrated in studies that found higher RPS15 expression in tumors compared to normal tissues (t-test, P = 6.00E−45) and correlation with lymph node metastasis (Fisher exact test, P = 0.018) .

How does RPS15 contribute to cancer progression according to latest research?

Recent studies have revealed significant insights into RPS15's role in cancer progression. RPS15 has been identified as a critical promoter of esophageal squamous cell carcinoma (ESCC) through multiple mechanisms:

• Enhanced cell migration and invasion: Overexpression of RPS15 substantially increases migration and invasion abilities of ESCC cells, while RPS15 knockout significantly decreases these metastatic properties. Quantitative phase imaging demonstrates that RPS15 overexpression increases track speed and movement ability of ESCC cells .

• Accelerated proliferation: RPS15 overexpression promotes cell mitosis events and reduces cell-doubling time in ESCC cells, while RPS15 depletion has opposite effects. Specifically, experiments showed that knockdown of RPS15 using siRNA significantly decreases cell proliferation abilities .

• In vivo tumor growth and metastasis: In mouse models, RPS15 overexpression significantly enhances tumor growth rate (measured by tumor weight and volume, t-test, P < 0.05). In popliteal lymph node metastasis models, RPS15 overexpression significantly increases lymphatic metastasis as measured by lymph node weights and volumes .

• Molecular mechanism: RPS15 interacts with IGF2BP1 to promote stabilization of MKK6 and MAPK14 mRNA in an m6A-dependent manner, enhancing translation of core p38 MAPK pathway proteins that drive ESCC progression .

What is the prognostic value of RPS15 expression in cancer patients?

The prognostic significance of RPS15 expression has been established through comprehensive clinical studies, particularly in esophageal squamous cell carcinoma (ESCC). Immunohistochemical analysis of tissue microarrays (TMAs) containing 504 ESCC specimens revealed significantly higher expression of RPS15 in tumors compared to normal tissue (t-test, P = 6.00E−45) .

Most significantly, Kaplan-Meier survival analysis demonstrated that high RPS15 expression in ESCC patients significantly correlated with poor prognosis . This statistical association remained significant after controlling for other clinical variables, establishing RPS15 as an independent prognostic factor.

The prognostic value extends to metastatic potential, as increased RPS15 expression was significantly correlated with lymph node metastasis (Fisher exact test, P = 0.018) . This relationship between RPS15 expression and metastasis provides a molecular basis for its prognostic value, as lymph node involvement is a critical determinant of cancer staging and patient outcomes.

These findings suggest that RPS15 immunohistochemistry using validated antibodies could be developed as a clinical tool for risk stratification in ESCC patients, potentially guiding treatment decisions based on expression levels.

What therapeutic approaches targeting RPS15 are being investigated?

Emerging research has identified several promising therapeutic approaches targeting RPS15:

• Small molecule inhibitors: Through targeted drug virtual screening and functional assays, researchers discovered that folic acid demonstrates therapeutic effects on ESCC by targeting RPS15. This effect was significantly enhanced when combined with cisplatin, suggesting potential for combination therapy approaches .

• p38 MAPK pathway inhibition: Given that RPS15 promotes ESCC progression via the p38 MAPK signaling pathway, inhibition using SB203580 (a p38 MAPK inhibitor) has shown efficacy in suppressing ESCC metastasis and proliferation in RPS15-overexpressing models .

• RNA-binding protein targeting: Since RPS15 interacts with IGF2BP1 to promote mRNA stability, IGF2BP1 ablation represents another approach to counteract RPS15-mediated oncogenic effects. Research has shown that this approach can suppress ESCC metastasis and proliferation .

• Combined approaches: The most effective strategies appear to combine multiple approaches. Research demonstrated that inhibition of RPS15 by folic acid, combined with either IGF2BP1 ablation or SB203580 treatment, provides superior suppression of ESCC progression compared to single-agent approaches .

While these approaches are still in preclinical development, they represent promising avenues for translating the molecular understanding of RPS15 function into therapeutic strategies for cancer patients, particularly those with high RPS15 expression.

What emerging applications of RPS15 antibodies should researchers consider?

As molecular biology techniques continue to advance, several emerging applications for RPS15 antibodies warrant consideration:

• Spatial proteomics: Combining RPS15 antibodies with multiplexed imaging techniques like CODEX or Imaging Mass Cytometry could reveal subcellular localization patterns and protein-protein interactions in intact tissues with unprecedented resolution.

• Liquid biopsy development: RPS15 antibodies might be utilized in the development of assays to detect circulating tumor cells or extracellular vesicles expressing RPS15, potentially providing non-invasive biomarkers for cancers where RPS15 overexpression has prognostic significance .

• Drug-target engagement studies: As therapeutic approaches targeting RPS15 develop , antibodies will be crucial for confirming target engagement in both preclinical models and clinical samples.

• Single-cell proteomics: Integration of RPS15 antibodies into single-cell Western blotting or antibody-based single-cell proteomics platforms could reveal cell-to-cell heterogeneity in RPS15 expression and its correlation with cellular phenotypes.

• Proximity labeling approaches: Combining RPS15 antibodies with techniques like proximity ligation assay (PLA) or BioID could map the dynamic interactome of RPS15 in different cellular contexts, further elucidating its non-canonical functions beyond the ribosome.

How might technical advances in antibody development improve RPS15 research?

Future technical advances in antibody development could significantly enhance RPS15 research:

• Recombinant antibody technology: Development of recombinant RPS15 antibodies would address batch-to-batch variability issues inherent to polyclonal antibodies, providing more consistent results across studies.

• Epitope-specific monoclonal antibodies: Generation of monoclonal antibodies targeting different RPS15 epitopes could distinguish between various functional states or post-translational modifications, offering deeper mechanistic insights.

• Intrabodies and nanobodies: Development of RPS15-specific intrabodies or nanobodies would enable live-cell imaging of RPS15 dynamics and potentially disrupt specific protein-protein interactions for functional studies.

• Antibody-drug conjugates: For therapeutic applications, RPS15 antibodies could be developed into antibody-drug conjugates specifically targeting cancer cells with high RPS15 expression, building on findings that high RPS15 expression correlates with poor prognosis in certain cancers .

• Antibody fragments with enhanced tissue penetration: Smaller antibody formats could improve tissue penetration in both imaging and therapeutic applications, particularly important given RPS15's identification as a potential therapeutic target .